Formycon AG/€FYB

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Formycon AG

Formycon AG is a biotechnology company based in Planegg, Germany, specializing in the development of biosimilar products. The company focuses primarily on creating biosimilar versions of top-selling biopharmaceuticals, addressing fields such as ophthalmology and immunology. Known for its significant expertise in protein and biopharmaceutical development, Formycon leverages its proprietary technical platform to advance its biosimilar pipeline. The company's strategic positioning includes partnerships with other pharmaceutical firms to co-develop and commercialize its biosimilar candidates. Formycon's competitive strength lies in its robust development capabilities and focus on high-growth therapeutic areas.

Ticker

€FYB

Primary listing

XETRA

Industry

Biotechnology
Headquarters

Employees

250

Formycon AG Metrics

BasicAdvanced
€497M
-
-€7.18
0.60
-

Bulls say / Bears say

Formycon's biosimilar FYB201 (CIMERLI®) achieved a 38% market share in the U.S. by December 2023, indicating strong market acceptance and potential for revenue growth. (ayondo.com)
The strategic investment by Gedeon Richter, acquiring a 9.1% stake in Formycon, provides significant capital infusion and opens avenues for collaborative development and commercialization. (formycon.com)
Formycon's uplisting to the Prime Standard and subsequent inclusion in the SDAX and TecDAX indices enhance its visibility and credibility among investors, potentially attracting more institutional investment. (formycon.com)
Despite increased revenues, Formycon reported a Group EBITDA of €-13.7 million for 2024, reflecting ongoing operational losses that may concern investors. (formycon.com)
The biosimilar market is highly competitive, and Formycon's products face challenges from both established pharmaceutical companies and other biosimilar developers, potentially impacting market share and pricing power. (formycon.com)
Regulatory approvals for biosimilars can be unpredictable, and any delays or rejections in Formycon's pipeline could adversely affect its financial performance and stock value. (formycon.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FYB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs